(LIFCO-B) Lifco (publ) - Ratings and Ratios
Dental Equipment, Demolition Robots, Tools, Machinery, Electronic Components
LIFCO-B EPS (Earnings per Share)
LIFCO-B Revenue
Description: LIFCO-B Lifco (publ)
Lifco AB (publ) is a Swedish industrial conglomerate with a diverse portfolio of businesses, including dental, demolition and tools, and systems solutions. The company operates globally, with a presence in Europe, Asia, Australia, North America, and internationally.
The dental segment involves the distribution of dental equipment and consumables, as well as the operation of a dental laboratory and provision of technical and software services. Lifco also develops and sells medical record systems, indicating a strong focus on healthcare technology.
In the demolition and tools segment, Lifco develops, manufactures, and sells demolition robots, forest machines, and crane and excavator attachments to various industries, including heavy machine manufacturing, infrastructure, and construction.
The systems solutions segment offers a wide range of products, including machinery and equipment for electrical installations, electrical equipment, and equipment for recycling various materials. Lifco also provides contract manufacturing, environmental technology, and infrastructure products, as well as special products and transportation products.
From a financial perspective, Lifcos market capitalization is approximately 162.6 billion SEK, with a return on equity (RoE) of 19.87%. To further evaluate the companys performance, we can examine additional key performance indicators (KPIs) such as revenue growth, operating margin, and debt-to-equity ratio.
Assuming Lifcos revenue growth is stable, a high P/E ratio of 48.59 may indicate that the market expects strong future growth. To validate this, we can analyze the companys historical revenue growth rate and compare it to industry peers. Additionally, an analysis of Lifcos operating margin and return on assets (RoA) can provide insights into its operational efficiency and asset utilization.
To assess Lifcos financial health, we can examine its debt-to-equity ratio and interest coverage ratio. A relatively low debt-to-equity ratio would indicate a healthy balance sheet, while a high interest coverage ratio would suggest that the company can comfortably service its debt.
LIFCO-B Stock Overview
| Market Cap in USD | 16,404m |
| Sub-Industry | Industrial Conglomerates |
| IPO / Inception |
LIFCO-B Stock Ratings
| Growth Rating | 81.6 |
| Fundamental | 76.8% |
| Dividend Rating | 30.8 |
| Rel. Strength | -6.75 |
| Analysts | - |
| Fair Price Momentum | 333.60 SEK |
| Fair Price DCF | 201.33 SEK |
LIFCO-B Dividends
| Dividend Yield 12m | 0.70% |
| Yield on Cost 5y | 1.83% |
| Annual Growth 5y | -19.73% |
| Payout Consistency | 96.6% |
| Payout Ratio | 31.7% |
LIFCO-B Growth Ratios
| Growth Correlation 3m | -83% |
| Growth Correlation 12m | 72.3% |
| Growth Correlation 5y | 81.1% |
| CAGR 5y | 21.26% |
| CAGR/Max DD 5y | 0.46 |
| Sharpe Ratio 12m | 0.11 |
| Alpha | -3.38 |
| Beta | 0.865 |
| Volatility | 32.63% |
| Current Volume | 207.1k |
| Average Volume 20d | 221.5k |
| Stop Loss | 333.6 (-3%) |
| Signal | -0.40 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (3.41b TTM) > 0 and > 6% of Revenue (6% = 1.64b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -0.96pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.89% (prev -9.67%; Δ 3.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 4.51b > Net Income 3.41b (YES >=105%, WARN >=100%) |
| Net Debt (-1.21b) to EBITDA (6.05b) ratio: -0.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (455.0m) change vs 12m ago 0.09% (target <= -2.0% for YES) |
| Gross Margin 43.91% (prev 44.56%; Δ -0.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.41% (prev 66.79%; Δ 3.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.98 (EBITDA TTM 6.05b / Interest Expense TTM 418.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.83
| (A) -0.04 = (Total Current Assets 10.74b - Total Current Liabilities 12.35b) / Total Assets 40.04b |
| (B) 0.41 = Retained Earnings (Balance) 16.61b / Total Assets 40.04b |
| (C) 0.13 = EBIT TTM 5.01b / Avg Total Assets 38.75b |
| (D) 0.83 = Book Value of Equity 18.26b / Total Liabilities 21.99b |
| Total Rating: 2.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.80
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 2.46% = 1.23 |
| 3. FCF Margin 15.02% = 3.75 |
| 4. Debt/Equity 0.63 = 2.31 |
| 5. Debt/Ebitda 1.87 = 0.26 |
| 6. ROIC - WACC 7.73% = 9.66 |
| 7. RoE 19.24% = 1.60 |
| 8. Rev. Trend 84.95% = 4.25 |
| 9. Rev. CAGR 11.42% = 1.43 |
| 10. EPS Trend 54.77% = 1.37 |
| 11. EPS CAGR 9.37% = 0.94 |
What is the price of LIFCO-B shares?
Over the past week, the price has changed by -0.17%, over one month by -3.43%, over three months by -14.98% and over the past year by +11.92%.
Is Lifco (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LIFCO-B is around 333.60 SEK . This means that LIFCO-B is currently overvalued and has a potential downside of -3.02%.
Is LIFCO-B a buy, sell or hold?
What are the forecasts/targets for the LIFCO-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 395.5 | 15% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 372.4 | 8.3% |
LIFCO-B Fundamental Data Overview
Market Cap SEK = 156.52b (156.52b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 1.21b SEK (last quarter)
P/E Trailing = 45.8855
P/S = 5.7374
P/B = 8.7316
Beta = 1.178
Revenue TTM = 27.28b SEK
EBIT TTM = 5.01b SEK
EBITDA TTM = 6.05b SEK
Long Term Debt = 4.26b SEK (from longTermDebt, last quarter)
Short Term Debt = 7.03b SEK (from shortTermDebt, last quarter)
Debt = 11.29b SEK (Calculated: Short Term 7.03b + Long Term 4.26b)
Net Debt = -1.21b SEK (from netDebt column, last quarter)
Enterprise Value = 166.60b SEK (156.52b + Debt 11.29b - CCE 1.21b)
Interest Coverage Ratio = 11.98 (Ebit TTM 5.01b / Interest Expense TTM 418.0m)
FCF Yield = 2.46% (FCF TTM 4.10b / Enterprise Value 166.60b)
FCF Margin = 15.02% (FCF TTM 4.10b / Revenue TTM 27.28b)
Net Margin = 12.51% (Net Income TTM 3.41b / Revenue TTM 27.28b)
Gross Margin = 43.91% ((Revenue TTM 27.28b - Cost of Revenue TTM 15.30b) / Revenue TTM)
Tobins Q-Ratio = 9.13 (Enterprise Value 166.60b / Book Value Of Equity 18.26b)
Interest Expense / Debt = 0.91% (Interest Expense 103.0m / Debt 11.29b)
Taxrate = 24.81% (from yearly Income Tax Expense: 1.10b / 4.45b)
NOPAT = 3.77b (EBIT 5.01b * (1 - 24.81%))
Current Ratio = 0.87 (Total Current Assets 10.74b / Total Current Liabilities 12.35b)
Debt / Equity = 0.63 (Debt 11.29b / last Quarter total Stockholder Equity 17.93b)
Debt / EBITDA = 1.87 (Net Debt -1.21b / EBITDA 6.05b)
Debt / FCF = 2.76 (Debt 11.29b / FCF TTM 4.10b)
Total Stockholder Equity = 17.74b (last 4 quarters mean)
RoA = 8.53% (Net Income 3.41b, Total Assets 40.04b )
RoE = 19.24% (Net Income TTM 3.41b / Total Stockholder Equity 17.74b)
RoCE = 22.76% (Ebit 5.01b / (Equity 17.74b + L.T.Debt 4.26b))
RoIC = 16.36% (NOPAT 3.77b / Invested Capital 23.03b)
WACC = 8.63% (E(156.52b)/V(167.81b) * Re(9.20%)) + (D(11.29b)/V(167.81b) * Rd(0.91%) * (1-Tc(0.25)))
Shares Correlation 5-Years: -5.10 | Cagr: -0.01%
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.87% ; FCFE base≈4.14b ; Y1≈4.60b ; Y5≈6.05b
Fair Price DCF = 201.3 (DCF Value 85.33b / Shares Outstanding 423.8m; 5y FCF grow 13.06% → 3.0% )
Revenue Correlation: 84.95 | Revenue CAGR: 11.42%
Revenue Growth Correlation: -12.69%
EPS Correlation: 54.77 | EPS CAGR: 9.37%
EPS Growth Correlation: -10.95%